Literature DB >> 26209360

Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells.

Yu Jin Jeon1, Joong Sun Kim2, Geun Hye Hwang1, Zhexue Wu1, Ho Jae Han3, Soo Hyun Park4, Woochul Chang5, Lark Kyun Kim6, You-Mie Lee1, Kwang-Hyeon Liu7, Min Young Lee8.   

Abstract

Cytochrome P450 2J2 (CYP2J2) is highly expressed in human tumors and carcinoma cell lines, and has been implicated in the pathogenesis of human cancers. The aim of this study was to identify a compound that could inhibit the activity of CYP2J2, and to examine its anticancer activity. To identify CYP2J2 inhibitors, 10 terpenoids obtained from plants were screened using astemizole as a CYP2J2 probe substrate in human liver microsomes (HLMs). Of these, tanshinone IIA dose-dependently and non-competitively inhibited CYP2J2-mediated astemizole O-demethylation activity. Tanshinone IIA significantly decreased viability of human hepatoma HepG2 cells and SiHa cervical cancer cells; however, it was not cytotoxic against mouse hepatocytes. Furthermore, treatment of cells with tanshinone IIA significantly increased apoptotic cell death rate, as shown by the increase in Annexin V-stained cell populations, Bcl-2 associated X protein (Bax)/B-cell lymphoma 2 (Bcl-2) ratio, and poly (ADP-ribose) polymerase 1 (PARP-1) cleavage in HepG2 cells. Furthermore, the results of this study showed that tanshinone IIA significantly decreased HepG2 cell-based tumor growth in nude mice in a dose-dependent manner. On the other hand, the tanshinone IIA-induced apoptotic cell death rate was significantly attenuated by enhanced up-regulation of CYP2J2 expression. Thus, our data strongly suggest that tanshinone IIA exerts its anticancer effect by inhibiting CYP2J2 activity.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anticancer; Apoptosis; Cytochrome P450 2J2; HepG2 cells; Tanshinone IIA

Mesh:

Substances:

Year:  2015        PMID: 26209360     DOI: 10.1016/j.ejphar.2015.07.047

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  CYP2J2 promotes the development of hepatocellular carcinoma by increasing the EETs production to improve HIF-1α stability.

Authors:  Liang Gui; Qiang Xu; Juju Huang; Gaojue Wu; Hong Tang; Li Hui; Ping Hua; Lili Zhang; Yingwei Zhu
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

2.  Tanshinone IIA induces cell death via Beclin-1-dependent autophagy in oral squamous cell carcinoma SCC-9 cell line.

Authors:  Ye Qiu; Conghua Li; Qinhua Wang; Xingqi Zeng; Ping Ji
Journal:  Cancer Med       Date:  2018-01-06       Impact factor: 4.452

Review 3.  A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease.

Authors:  Zhaojian Zhang; Yu Wang; Wangxiao Tan; Siwei Wang; Jinghua Liu; Xiao Liu; Xiaoying Wang; Xiumei Gao
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-19       Impact factor: 2.629

4.  Tanshinone IIA reverses EGF- and TGF-β1-mediated epithelial-mesenchymal transition in HepG2 cells via the PI3K/Akt/ERK signaling pathway.

Authors:  Longkai Zhang; Weibin Lin; Xiaodan Chen; Gang Wei; Hailong Zhu; Shangping Xing
Journal:  Oncol Lett       Date:  2019-11-01       Impact factor: 2.967

5.  Cytochrome P450 2A6 is associated with macrophage polarization and is a potential biomarker for hepatocellular carcinoma.

Authors:  Tao Jiang; Ai-Song Zhu; Chu-Qi Yang; Chu-Yun Xu; Dan-Qian Yang; Zhao-Huan Lou; Guang-Ji Zhang
Journal:  FEBS Open Bio       Date:  2021-02-05       Impact factor: 2.693

6.  Acetylshikonin, A Novel CYP2J2 Inhibitor, Induces Apoptosis in RCC Cells via FOXO3 Activation and ROS Elevation.

Authors:  Heui Min Lim; Jongsung Lee; Seon Hak Yu; Myeong Jin Nam; Hyo Sun Cha; Kyungmoon Park; Yung-Hun Yang; Kyu Yun Jang; See-Hyoung Park
Journal:  Oxid Med Cell Longev       Date:  2022-03-09       Impact factor: 6.543

Review 7.  An overview of the anti-cancer actions of Tanshinones, derived from Salvia miltiorrhiza (Danshen).

Authors:  Irum Naz; Myriam Merarchi; Shanaya Ramchandani; Muhammad Rashid Khan; Muhammad Nouman Malik; Sumaira Sarwar; Acharan S Narula; Kwang Seok Ahn
Journal:  Explor Target Antitumor Ther       Date:  2020-06-29

8.  The Synergistic Antitumor Effect of Tanshinone IIA Plus Adriamycin on Human Hepatocellular Carcinoma Xenograft in BALB/C Nude Mice and Their Influences on Cytochrome P450 CYP3A4 In Vivo.

Authors:  Tao-Li Liu; Li-Na Zhang; Yue-Yu Gu; Mei-Gui Lin; Jun Xie; Yu-Ling Chen; Jia-Hui Liu; Xin-Lin Wu; Sui-Lin Mo
Journal:  Adv Med       Date:  2020-02-29

9.  Simultaneous induction of apoptosis and necroptosis by Tanshinone IIA in human hepatocellular carcinoma HepG2 cells.

Authors:  C-Y Lin; T-W Chang; W-H Hsieh; M-C Hung; I-H Lin; S-C Lai; Y-J Tzeng
Journal:  Cell Death Discov       Date:  2016-10-03

10.  Galactose-Modified PH-Sensitive Niosomes for Controlled Release and Hepatocellular Carcinoma Target Delivery of Tanshinone IIA.

Authors:  Xixi Hu; Jun Zhang; Lulu Deng; Hao Hu; Junjie Hu; Guohua Zheng
Journal:  AAPS PharmSciTech       Date:  2021-03-10       Impact factor: 3.246

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.